Navigation Links
Sunesis Presents Data Supporting SNS-032's Potential Anticancer,Activity in Multiple Myeloma at the American Association for Cancer,Research Meeting

Results from Non-clinical Studies Confirm Mechanism of Action and Provide Guidance for Dosing

SOUTH SAN FRANCISCO, April 16, 2007 /PRNewswire-FirstCall/ -- Sunesis Pharmaceuticals, Inc. presented non-clinical data demonstrating SNS-032's apoptotic activity in a multiple myeloma model. These data were presented today in a poster session during the Annual Meeting of the American Association for Cancer Research (AACR).

SNS-032, a selective and potent inhibitor of cyclin-dependent kinases (CDKs) 2, 7 and 9, is currently in a Phase 1 clinical trial for B-cell malignancies, including chronic lymphocytic leukemia, multiple myeloma and mantle cell lymphoma. Non-clinical studies were conducted by Sunesis evaluating SNS-032's mechanism of action and in vitro activity against human multiple myeloma cell line RPMI-8226. Acting through inhibition of CDKs 2, 7, and 9, SNS-032 blocks both the cell cycle and transcription to drive apoptosis, or programmed cell death, in multiple myeloma cells upon exposure for six hours. Researchers also noted that exposure to SNS-032 induced down regulation of key anti-apoptotic factors, cell survival proteins, and growth factors that drive the disease. These results confirm that inhibiting CDKs 2, 7 and 9 targets both unregulated cell proliferation and the microenvironment associated with multiple myeloma and support the dosing regimen currently in use in the company's Phase 1 B-cell malignancy clinical trial.

"Data presented today from our non-clinical study of SNS-032 in multiple myeloma cell lines support our hypothesis that targeted inhibition of CDKs 2, 7 and 9 triggers cell death in hematologic cancer," said Daniel C. Adelman, M.D., Senior Vice President, Research and Development. "In addition, these results provide a pharmacologic basis for the dosing regimen being used in our Phase 1 clinical study, and identify potential biomarkers for monitoring activity."

Data
'"/>




Page: 1 2 3

Related medicine technology :

1. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
2. Sunesis Pharmaceuticals Reports Positive Data From Studies of Two Anti-Cancer Agents, SNS-595 and SNS-032, at the 12th Congress of the European Hematology Association
3. Sunesis Pharmaceuticals to Present Data at the 12th Congress of the European Hematology Association
4. Sunesis Pharmaceuticals to Present Data at the Annual Meeting of the American Association for Cancer Research
5. Sunesis Pharmaceuticals Presents SNS-314 Aurora Kinase Inhibitor Data Showing Broad Anti-Tumor Activity, Dosing Flexibility
6. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
7. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
8. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
9. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
10. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
11. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
Post Your Comments:
(Date:7/30/2015)... July 30, 2015  ResMed (NYSE: ... a definitive agreement to acquire Curative Medical, ... and sleep-disordered breathing medical devices and accessories. ... in China, combined with ResMed,s global leadership in sleep and respiratory ... China suffering from sleep-disordered ...
(Date:7/30/2015)... 30, 2015  EP Global Communications, Inc. (Public OTC: ... contacted the Company about discussing EPGL,s electronic contact ... Monday, August 3, 2015.  Novartis CEO Joe ... the coming electronic contact lens market could be ... next several years.  Novartis partnered with Google in ...
(Date:7/30/2015)... July 30, 2015  Amgen (NASDAQ: AMGN ... quarter of 2015. Key results include: , ... quarter of 2014 to $5,370 million, with 6 ... ® (etanercept), Prolia ® (denosumab), Sensipar ... XGEVA ® (denosumab). Unfavorable changes in foreign ...
Breaking Medicine Technology:ResMed Invests in High-Growth Chinese Sleep and Respiratory Care Market with Curative Medical 2ResMed Invests in High-Growth Chinese Sleep and Respiratory Care Market with Curative Medical 3Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 2Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 3Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 4Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 5Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 6Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 7Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 8Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 9Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 10Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 11Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 12Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 13Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 14Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 15Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 16Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 17Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 18Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 19Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 20Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 21Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 22Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 23
... , HAYWARD, Calif., Nov. 17 ... today announced that its readerless CD4 point-of-care (POC) technology ... as the best-performing POC test method for measuring CD4 T-cell ... only remaining POC product being supported by the CD4 Initiative. ...
... , BEDFORD, Mass., Nov. 16 Hologic, ... a leading developer, manufacturer and supplier of premium diagnostics, ... the healthcare needs of women, is participating in the ... November 15-19, 2009 in Orlando, Florida, and will feature ...
Cached Medicine Technology:Zyomyx Point-of-Care CD4 Test Selected by CD4 Initiative to Help Treat HIV/AIDS Patients in Developing Countries 2Zyomyx Point-of-Care CD4 Test Selected by CD4 Initiative to Help Treat HIV/AIDS Patients in Developing Countries 3Hologic to Feature Adiana(R) Permanent Contraception System at AAGL 2009 2Hologic to Feature Adiana(R) Permanent Contraception System at AAGL 2009 3Hologic to Feature Adiana(R) Permanent Contraception System at AAGL 2009 4
(Date:7/30/2015)... ... July 30, 2015 , ... The Beryl Institute ... Program. In partnership with Patient Experience Institute, these offerings reinforce the commitment to ... front lines and throughout the experience movement, and provide information and research to ...
(Date:7/30/2015)... Melbourne, FL (PRWEB) , ... July 30, 2015 , ... ... Central Florida’s (UCF) College of Medicine as Assistant Professor of Plastic Surgery. This ... years, Dr. Clevens has worked closely with the university, developing a strong presence and ...
(Date:7/30/2015)... ... July 30, 2015 , ... ... ‘Mary Jo Lawyer-Spano Mesothelioma Patient Registry Act of 2015’. The bill was introduced ... (R-NY), Peter King (R-NY), Betty McCollum (D-MN), Joe Kennedy (D-MA), and Leonard Lance ...
(Date:7/30/2015)... ... July 30, 2015 , ... Using the latest online digital ... people more effective ways to prevent and manage major depression. , “Suicide is 100% ... so people fall through the cracks and die needlessly everyday,” says Walker. “I’m out ...
(Date:7/30/2015)... ... July 30, 2015 , ... ... Partners All-Star at the annual All-Stars Summit. Google Partners is the platform for ... may receive the full support and tools necessary to run successful search marketing ...
Breaking Medicine News(10 mins):Health News:The Beryl Institute Opens Applications for 2015 Patient Experience Grant and Scholar Programs 2Health News:The Beryl Institute Opens Applications for 2015 Patient Experience Grant and Scholar Programs 3Health News:Leading Melbourne Facial Plastic Surgeon Reappointed by UCF 2Health News:Leading Melbourne Facial Plastic Surgeon Reappointed by UCF 3Health News:Bill to Create Patient Registry for Deadly Cancer Introduced in Congress 2Health News:Happiness Expert Develops Pioneering Online Tools for Sufferers of Major Depression, and Who may be Suicidal 2Health News:Happiness Expert Develops Pioneering Online Tools for Sufferers of Major Depression, and Who may be Suicidal 3Health News:Boston Web Marketing Attends Google Partners All-Stars Summit 2
... (BIDMC) has been awarded a grant from the National ... the National Institutes of Health, to lead a Consortium ... grant totals $36 million. BIDMC Chief of Vaccine ... Medicine at Harvard Medical School, will co-lead the new ...
... Bristol-Myers Squibb Company announced results from a long-term, ... (ARV)-experienced patients (336 female and 958 male) from ... at the Sixth International AIDS Society Conference on ... In a gender-specific sub-analysis, boosted REYATAZ (atazanavir sulphate) ...
... (HealthDay News) -- Personality traits may play key roles in ... from the U.S. National Institute on Aging found that people ... to be overweight. And those who are highly neurotic and ... many ups and downs. "Individuals with this constellation of ...
... , TUESDAY, July 19 (HealthDay News) -- People who ... able to decide what they like or don,t like more ... the study, published in the Journal of Consumer Research ... either likable subjects (puppies) or unpleasant things (diseased feet) or ...
... falling into poverty is an increasingly common experience among ... jointly by the Heller School,s Institute on Assets and ... organization Demos. And, researchers say, the situation could ... The report, "From Bad to Worse: Senior Economic ...
... large waist size is unhealthy for anyone, but for kidney disease ... of dying, a new study reports. The study doesn,t ... it suggests there may be a link. In their ... aged 45 and older who had kidney disease. The patients were ...
Cached Medicine News:Health News:In the real life setting, boosted REYATAZ proves as effective in women living with HIV as men 2Health News:Does Your Personality Dictate Whether You'll Be Overweight? 2Health News:Happy Shoppers More Decisive When Purchasing 2Health News:New report shows seniors' economic security falling 2Health News:As Waistline Expands, So Does Death Risk for Kidney Patients 2
... the use of plates and screws in the treatment ... pins in the forearm or ankle is not a ... lock the pins or hold them in place. A ... out of the implant. The SST® (Stainless Steel Taper) ...
... 36 cc and 73 grams, the Epic ... care and simplified follow-up. The Epic HF ... 30 joule (delivered energy) biventricular ICD. Small ... HF ICD features advanced resynchronization parameters along ...
... has greatly enhanced the stabilization ... Biomet Low Profile Tibial Nail ... treatment of unstable fractures, tibial ... pathologic or impending fractures but ...
The Charlotte Shoulder™ System address arthroscopic, mini-open and open procedures with time saving instrumentation....
Medicine Products: